Home / Resources (page 31)

Resources

RESOURCES

GLP-1s and Inflammatory Arthritis: What Early Signals Mean for Diabetes Care

GLP-1 injection pen next to inflamed knee joints illustrating the relationship between GLP-1 therapy and inflammatory arthritis in diabetes care

A patient with type 2 diabetes finally achieves better glycemic control on a GLP-1 receptor agonist. Weight is coming down, A1C is improving, and cardiovascular risk looks more manageable. Then an unexpected comment appears at a follow-up visit. Their joints feel better. For clinicians, moments like this raise an important …

Read More »

GLP-1s and Hypertension: Can Incretins Help Bring Blood Pressure to Goal?

GLP-1 injection pen next to blood pressure monitor showing controlled systolic and diastolic readings

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …

Read More »

Beyond Coverage: How GLP‑1s, Tech, and AI Are Reshaping Diabetes Equity in 2026

Diverse healthcare professionals and patients interacting with diabetes technology, symbolizing equitable access in 2026.

What happens when breakthrough treatments only reach the few who can afford or access them? That’s the growing dilemma in diabetes care. As GLP‑1 medications, digital tools, and AI reshape how we treat this chronic disease, the risk is clear: innovation could deepen inequality if we don’t act intentionally. Equity …

Read More »

CKM in the Wild: Applying the 2026 ADA Cardiometabolic Framework to a Real Panel

Three diverse physicians collaborating with digital icons representing heart, kidney, and glucose care, symbolizing CKM ADA 2026 integration.

What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …

Read More »

AI‑First Clinics: What Happens When Algorithms Drive Most of the Diabetes Visit?

A doctor and patient discussing diabetes care with a futuristic AI dashboard displaying CGM and treatment data in a modern clinic.

What if your next diabetes appointment started before you even walked in—an algorithm already having reviewed your CGM data, flagged risks, and drafted a care plan? That’s not science fiction. It’s the emerging reality of AI-powered workflows for diabetes care, where intelligent systems work behind the scenes to support clinicians …

Read More »

Talking About Off‑Label GLP‑1 Use: How to Answer Patients Without Overpromising

Doctor discussing GLP-1 off-label medication options with a patient in a clinical setting, with injection pens and research charts visible.

A patient walks into your exam room, hopeful after reading that a diabetes drug might help with memory loss, addiction, or even anxiety. You know they’re talking about GLP‑1s—but how do you respond when the science is still unfolding? As GLP‑1 receptor agonists capture public attention for much more than …

Read More »

GLP‑1 Stewardship in the Clinic: Prioritizing, Deprescribing, and Switching Without Chaos

Medical concept featuring GLP-1 medication, injection pens, stethoscope, and clinic policy checklists on a desk

What happens when a breakthrough therapy becomes too popular for its own good? Clinics across the country are struggling to manage demand for GLP‑1 receptor agonists amid soaring prescriptions, medication shortages, and shifting insurance coverage. Without a strategy, patients fall through the cracks—and providers are left making chaotic case-by-case decisions. …

Read More »

GLP‑1s on the WHO Radar: Turning Global Guidance Into Everyday Prescribing

GLP‑1 medication pen and stethoscope on a world map with WHO logo in background

What happens when a once-costly, class-specific treatment becomes a global health priority? That’s the question raised by the World Health Organization’s latest move: recognizing GLP‑1 receptor agonists as essential medicines and issuing new recommendations for their use in obesity and diabetes care. These updated GLP‑1 WHO guidelines are more than …

Read More »

Oral and Long‑Acting GLP‑1s: What They Mean for Adherence and Follow‑Up

GLP‑1 pill bottle, injection pen, and patient chart on a doctor’s desk during a consultation

What happens when medications become easier to take—but harder to track? Oral and monthly GLP‑1 therapies promise fewer injections and less hassle, yet they may also create blind spots in patient care. As these long‑acting options reshape diabetes treatment, they’re also changing how clinicians must think about follow‑up, side effect …

Read More »

GLP‑1s for PAD: Using Incretins to Protect Limbs as Well as Hearts

Medical depiction of GLP‑1 treatment for peripheral artery disease showing a highlighted leg artery, GLP‑1 injection, and blocked artery inset.

Peripheral artery disease (PAD) affects millions of people with type 2 diabetes worldwide, increasing the risk of cardiovascular events and limb loss. With recent research into incretin‑based therapies, particularly glucagon‑like peptide‑1 receptor agonists (GLP‑1s), clinicians are asking whether these drugs can improve outcomes in PAD patients treated with GLP‑1s, beyond …

Read More »